{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:54:12Z","timestamp":1791536052265,"version":"4.3.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T00:00:00Z","timestamp":1545177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T00:00:00Z","timestamp":1545177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"crossref","award":["Oncology Research Program (ORP)"],"award-info":[{"award-number":["Oncology Research Program (ORP)"]}],"id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,8,15]]},"DOI":"10.1007\/s10637-018-0696-4","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T04:55:43Z","timestamp":1545195343000},"page":"702-710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma"],"prefix":"10.1007","volume":"37","author":[{"given":"Theodoros N.","family":"Teknos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Grecula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. O.","family":"Old","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ozer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Carrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Blakaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Diavolitsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Palettas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Savvides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,19]]},"reference":[{"issue":"1","key":"696_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2982","volume":"11","author":"CR Leemans","year":"2011","unstructured":"Leemans CR, Braakhuis BJM, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9\u201322","journal-title":"Nat Rev Cancer"},{"key":"696_CR2","doi-asserted-by":"publisher","first-page":"c4684","DOI":"10.1136\/bmj.c4684","volume":"341","author":"H Mehanna","year":"2010","unstructured":"Mehanna H, Paleri V, West CML, Nutting C (2010) Head and neck cancer-part 1: epidemiology, presentation, and prevention. BMJ 341:c4684","journal-title":"BMJ"},{"key":"696_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics. Cancer J Clin 66:271\u2013289","journal-title":"Cancer J Clin"},{"key":"696_CR4","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1158\/0008-5472.CAN-14-2843","volume":"75","author":"AK Chaturvedi","year":"2015","unstructured":"Chaturvedi AK, Graubard BI, Broutian T, Pickard RKL, Tong ZY, Xiao W, Kahle L, Gillison ML (2015) NHANES 2009-2012 findings: association of sexual behaviors with higher prevalence of oral oncogenic human papillomavirus infections in U.S. men. Cancer Res 75:2468\u20132477","journal-title":"Cancer Res"},{"key":"696_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.oraloncology.2010.03.007","volume":"46","author":"N Kalavrezos","year":"2010","unstructured":"Kalavrezos N, Bhandari R (2010) Current trends and future perspectives in the surgical management of oral cancer. Oral Oncol 46:429\u2013432","journal-title":"Oral Oncol"},{"issue":"19","key":"696_CR6","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/jnci\/dji289","volume":"97","author":"BK Edwards","year":"2005","unstructured":"Edwards BK, Brown ML, Wingo PA et al (2005) Annual report to the nation on the status of cancer, 1975\u20132002, featuring population based trends in cancer treatment. J Natl Cancer Inst. Oct 5 97(19):1407\u20131427","journal-title":"J Natl Cancer Inst"},{"key":"696_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-T\u00e2n PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24\u201335","journal-title":"N Engl J Med"},{"key":"696_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ijc.20740","volume":"114","author":"AL Carvalho","year":"2005","unstructured":"Carvalho AL, Hishimoto IN, Califano JA et al (2005) Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 114:806\u2013881","journal-title":"Int J Cancer"},{"issue":"1","key":"696_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/01.mlg.0000246191.90021.5e","volume":"117","author":"SF Preuss","year":"2007","unstructured":"Preuss SF, Quante G, Semrau R, Mueller RP, Klussmann JP, Guntinas-Lichius O (2007) An analysis of surgical complications, morbidity, and cost calculation in patients undergoing multimodal treatment for operable oropharyngeal carcinoma. Laryngoscope 117(1):101\u2013105","journal-title":"Laryngoscope"},{"issue":"9","key":"696_CR10","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1097\/01.mlg.0000175075.69706.64","volume":"115","author":"K Sundaram","year":"2005","unstructured":"Sundaram K, Schwartz J, Har-El G et al (2005) Carcinoma of the oropharynx: factors affecting outcome. Laryngoscope 115(9):1536\u20131542","journal-title":"Laryngoscope"},{"key":"696_CR11","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJM199106133242402","volume":"324","author":"GT Wolf","year":"1991","unstructured":"Wolf GT, Fisher SG, Hong WK et al (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: the department of veterans affairs laryngeal cancer study group. N Engl J Med 324:1685\u20131690","journal-title":"N Engl J Med"},{"key":"696_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.2005.01.2047","volume":"24","author":"S Urba","year":"2006","unstructured":"Urba S, Wolf G, Eisbruch A, Worden F, Lee J, Bradford C, Teknos T, Chepeha D, Prince M, Hogikyan N, Taylor J (2006) Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 24:593\u2013598","journal-title":"J Clin Oncol"},{"issue":"19","key":"696_CR13","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1200\/JCO.2007.12.7597","volume":"26","author":"FP Worden","year":"2008","unstructured":"Worden FP, Kumar B, Lee JS et al (2008) Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 26(19):3138\u20133146","journal-title":"J Clin Oncol"},{"key":"696_CR14","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1200\/JCO.2002.20.5.1405","volume":"20","author":"DJ Adelstein","year":"2002","unstructured":"Adelstein DJ, Saxton JP, Lavertu P, Rybicki LA, Esclamado RM, Wood BG, Strome M, Carroll MA (2002) Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer with hyperfractionated radiation and concurrent chemotherapy. J Clin Oncol 20:1405\u20131410","journal-title":"J Clin Oncol"},{"issue":"14","key":"696_CR15","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1200\/JCO.2004.12.012","volume":"22","author":"AS Garden","year":"2004","unstructured":"Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E (2004) Preliminary results of radiation therapy oncology group 9703: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 22(14):2856\u20132864","journal-title":"J Clin Oncol"},{"key":"696_CR16","doi-asserted-by":"crossref","unstructured":"Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G (2004 Jan 1) Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. Clin Oncol 22(1):69\u201376 Epub 2003 Dec 2","DOI":"10.1200\/JCO.2004.08.021"},{"key":"696_CR17","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1200\/JCO.2007.14.8841","volume":"26","author":"M Machtay","year":"2008","unstructured":"Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A, Ang KK (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26:3582\u20133589","journal-title":"J Clin Oncol"},{"key":"696_CR18","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-05-0480","volume":"5","author":"A Hrzenjak","year":"2006","unstructured":"Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K, Denk H (2006) Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5:2203\u20132210","journal-title":"Mol Cancer Ther"},{"key":"696_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","volume":"12","author":"BH Huang","year":"2005","unstructured":"Huang BH, Laban M, Leung CH et al (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1\/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12:395\u2013404","journal-title":"Cell Death Differ"},{"key":"696_CR20","doi-asserted-by":"publisher","first-page":"7982","DOI":"10.1128\/MCB.22.22.7982-7992.2002","volume":"22","author":"JJ Westendorf","year":"2002","unstructured":"Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, Yoshida M, Stein GS, Li X (2002) Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1\/WAF1) promoter. Mol Cell Biol 22:7982\u20137992","journal-title":"Mol Cell Biol"},{"key":"696_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/ng1531","volume":"37","author":"MF Fraga","year":"2005","unstructured":"Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, P\u00e9rez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris M\u00c1, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391\u2013400","journal-title":"Nat Genet"},{"key":"696_CR22","first-page":"1677","volume":"25","author":"SY Park","year":"2011","unstructured":"Park SY, Jun JA, Jeong KJ et al (2011) Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 25:1677\u20131168","journal-title":"Oncol Rep"},{"key":"696_CR23","doi-asserted-by":"publisher","first-page":"47844795","DOI":"10.1128\/MCB.00494-07","volume":"27","author":"S Senese","year":"2007","unstructured":"Senese S, Zaragoza K, Minardi S et al (2007) Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 27:47844795","journal-title":"Mol Cell Biol"},{"issue":"1","key":"696_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1078-0432.CCR-08-0684","volume":"15","author":"I Oehme","year":"2009","unstructured":"Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, Fischer M, Witt O (2009) Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res 15(1):91\u201399","journal-title":"Clin Cancer Res"},{"key":"696_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","volume":"10","author":"M Haberland","year":"2009","unstructured":"Haberland M, Montgomery RL, Olson EN (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10:32\u201342","journal-title":"Nat Rev Genet"},{"key":"696_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-3-642-21631-2_3","volume":"206","author":"L Peng","year":"2011","unstructured":"Peng L, Seto E (2011) Deacetylation of nonhistone proteins by HDACs and the implications in cancer. Handb Exp Pharmacol 206:39\u201356","journal-title":"Handb Exp Pharmacol"},{"key":"696_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/35106079","volume":"1","author":"P Marks","year":"2001","unstructured":"Marks P, Rifkind RA, Richon VM et al (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194\u2013202","journal-title":"Nat Rev Cancer"},{"key":"696_CR28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/jcb.20532","volume":"96","author":"M Dokmanovic","year":"2005","unstructured":"Dokmanovic M, Marks PA (2005) Prospects: histone deacetylase inhibitors. J Cell Biochem 96:293\u2013304","journal-title":"J Cell Biochem"},{"key":"696_CR29","first-page":"117","volume":"29","author":"S Takumi","year":"2006","unstructured":"Takumi S, Katsuhiro U, Takeshi O et al (2006) Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 29:117\u2013124","journal-title":"Int J Oncol"},{"key":"696_CR30","first-page":"1471","volume":"20","author":"UH Weidle","year":"2000","unstructured":"Weidle UH, Grossmann A (2000) Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res 20:1471\u20131485","journal-title":"Anticancer Res"},{"key":"696_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-2164-11-22","volume":"11","author":"KM Rothgiesser","year":"2010","unstructured":"Rothgiesser KM, Fey M, Hottiger MO (2010) Acetylation of p65 at lysine 314 is important for late NF-\u03baB-dependent gene expression. BMC Genomics 11:22","journal-title":"BMC Genomics"},{"issue":"5","key":"696_CR32","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/nar\/gkn003","volume":"36","author":"C Buerki","year":"2008","unstructured":"Buerki C, Rothgiesser KM, Valovka T, Owen HR, Rehrauer H, Fey M, Lane WS, Hottiger MO (2008) Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA\/p65. Nucleic Acids Res 36(5):1665\u20131680","journal-title":"Nucleic Acids Res"},{"key":"696_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1128\/MMBR.64.2.435-459.2000","volume":"64","author":"DE Sterner","year":"2000","unstructured":"Sterner DE, Berger SL (2000) Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 64:435\u2013459","journal-title":"Microbiol Mol Biol Rev"},{"key":"696_CR34","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.1242\/jcs.073783","volume":"123","author":"KM Rothgiesser","year":"2010","unstructured":"Rothgiesser KM, Erener S, Waibel S, Luscher B, Hottiger MO (2010) SIRT2 regulates NF-\u03baB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci 123:4251\u20134258","journal-title":"J Cell Sci"},{"key":"696_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0065-230X(02)86002-X","volume":"86","author":"H Lehrmann","year":"2002","unstructured":"Lehrmann H, Pritchard LL, Harel-Bellan A (2002) Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 86:41\u201365","journal-title":"Adv Cancer Res"},{"issue":"1","key":"696_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","volume":"338","author":"IV Gregoretti","year":"2004","unstructured":"Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338(1):17\u201331","journal-title":"J Mol Biol"},{"key":"696_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/icb.2011.100","volume":"90","author":"O Khan","year":"2012","unstructured":"Khan O, La Thangue NB (2012) HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90:85\u201394","journal-title":"Immunol Cell Biol"},{"issue":"2","key":"696_CR38","first-page":"166","volume":"3","author":"HJ Kim","year":"2011","unstructured":"Kim HJ, Bae SC (2011) Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anticancer drugs. Am J Transl Res 3(2):166\u2013179","journal-title":"Am J Transl Res"},{"issue":"1","key":"696_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","volume":"4","author":"RW Johnstone","year":"2003","unstructured":"Johnstone RW, Licht JD (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4(1):13\u201318","journal-title":"Cancer Cell"},{"key":"696_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West AC, Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124:30\u201339","journal-title":"J Clin Invest"},{"key":"696_CR41","doi-asserted-by":"crossref","unstructured":"Blumenschein GR, Kies MS, Papadimitrakopoulou VA et al Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinao, SAHA) in patients with recurrent and\/or metastatic head and neck cancer. Investig New Drugs 26(1):81\u201387","DOI":"10.1007\/s10637-007-9075-2"},{"issue":"11","key":"696_CR42","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1158\/1535-7163.MCT-04-0344","volume":"6","author":"AM Gillenwater","year":"2007","unstructured":"Gillenwater AM, Zhong M, Lotan R (2007) Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 6(11):2967\u20132975","journal-title":"Mol Cancer Ther"},{"key":"696_CR43","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1074\/jbc.M507213200","volume":"281","author":"Y Takada","year":"2006","unstructured":"Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB (2006) Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-{kappa}B activation. J Biol Chem 281:5612\u20135622","journal-title":"J Biol Chem"},{"issue":"17","key":"696_CR44","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.1158\/1078-0432.CCR-05-0344","volume":"11","author":"P Bali","year":"2005","unstructured":"Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K (2005) Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 11(17):6382\u20136389","journal-title":"Clin Cancer Res"},{"key":"696_CR45","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","volume":"23","author":"WK Kelly","year":"2005","unstructured":"Kelly WK, O\u2019Connor OA, Krug LM et al (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923\u20133931","journal-title":"J Clin Oncol"},{"issue":"3","key":"696_CR46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.18632\/genesandcancer.54","volume":"6","author":"B Kumar","year":"2015","unstructured":"Kumar B, Yadav A, Lang JC et al (2015) Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog. Genes and Cancer 6(3):169\u2013168","journal-title":"Genes and Cancer"},{"key":"696_CR47","first-page":"621628","volume":"40","author":"LL Tsai","year":"2014","unstructured":"Tsai LL, Yu CC, Chang YC et al (2014) Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 40:621628","journal-title":"J Oral Pathol Med"},{"key":"696_CR48","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1038\/onc.2013.209","volume":"33","author":"X Lu","year":"2014","unstructured":"Lu X, Mazur SJ, Lin T, Appella E, Xu Y (2014) The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis. Oncogene 33:2655\u20132664","journal-title":"Oncogene"},{"key":"696_CR49","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4161\/cbt.3.3.698","volume":"3","author":"YL Chung","year":"2004","unstructured":"Chung YL, Wang AJ, Yao LF (2004) Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther 3:317\u2013325","journal-title":"Mol Cancer Ther"},{"key":"696_CR50","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1073\/pnas.1011037108","volume":"108","author":"AJ Christiansen","year":"2011","unstructured":"Christiansen AJ, West A, Banks KM, Haynes NM, Teng MW, Smyth MJ, Johnstone RW (2011) Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A 108:4141\u20134146","journal-title":"Proc Natl Acad Sci U S A"},{"key":"696_CR51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2567.2007.02689.x","volume":"123","author":"J Manning","year":"2008","unstructured":"Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova J, Hejnar J, Simova J, Jandlova T, Bubenik J, Reinis M (2008) Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumors. Immunology 123:218\u2013227","journal-title":"Immunology"},{"key":"696_CR52","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/CCO.0b013e3280f01010","volume":"19","author":"J Bourhis","year":"2007","unstructured":"Bourhis J, LeMaitre A, Baujat B et al (2007) Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol 19:188\u2013194","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"696_CR53","first-page":"807","volume":"5","author":"BA Murphy","year":"2007","unstructured":"Murphy BA, Gilbert J, Cmelak A, Ridner SH (2007) Symptom control issues and supportive care of patients with head and neck cancers. Clin Adv Hematol Oncol 5(10):807\u2013822","journal-title":"Clin Adv Hematol Oncol"},{"key":"696_CR54","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0167-8140(02)00404-8","volume":"66","author":"A Trotti","year":"2003","unstructured":"Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66:253\u2013262","journal-title":"Radiother Oncol"},{"key":"696_CR55","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1002\/hed.24505","volume":"38","author":"T Maesschalck","year":"2016","unstructured":"Maesschalck T, Dulguerov N, Caparrotti F et al (2016) Comparison of the incidence of osteoradionecrosis with conventional radiotherapy and intensity-modulated radiotherapy. Head Neck 38:1695\u20131702","journal-title":"Head Neck"},{"key":"696_CR56","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/jmrs.132","volume":"62","author":"S Bishop","year":"2015","unstructured":"Bishop S, Reed WM (2015) The provision of enteral nutritional support during definitive chemoradiotherapy in head and neck cancer patients. J Med Radiat Sci 62:267\u2013276","journal-title":"J Med Radiat Sci"},{"key":"696_CR57","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1002\/cncr.27631","volume":"118","author":"KA Hutcheson","year":"2012","unstructured":"Hutcheson KA, Lewin JS, Barringer DA, Lisec A, Gunn GB, Moore MWS, Holsinger FC (2012) Late dysphagia after radiotherapy-based treatment of head and neck cancer. Cancer 118:5793\u20135799","journal-title":"Cancer"},{"key":"696_CR58","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","volume":"32","author":"KK Ang","year":"2014","unstructured":"Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, el-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32:2940\u20132950","journal-title":"J Clin Oncol"},{"key":"696_CR59","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1158\/1078-0432.CCR-07-0162","volume":"13","author":"SS Ramalingam","year":"2007","unstructured":"Ramalingam SS, Parise RA, Ramanathan RK et al (2007) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13:3605\u20133610","journal-title":"Clin Cancer Res"},{"key":"696_CR60","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.oraloncology.2012.05.024","volume":"48","author":"M Haigentz Jr","year":"2012","unstructured":"Haigentz M Jr, Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Chirieac LR, Mariadason JM, Belbin TJ, Greally JM, Wright JJ, Haddad RI (2012) Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent\/metastatic head and neck cancer. Oral Oncol 48:1281\u20131288","journal-title":"Oral Oncol"},{"issue":"1","key":"696_CR61","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1186\/s12885-016-2957-y","volume":"16","author":"F Caponigro","year":"2016","unstructured":"Caponigro F, Di Gennaro E, Ionna F et al (2016) Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and\/or metastatic squamous cell carcinoma of head and neck-V-CHANCE trial. BMC Cancer 16(1):918","journal-title":"BMC Cancer"},{"key":"696_CR62","first-page":"7291","volume":"63","author":"MS Kim","year":"2003","unstructured":"Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291\u20137300","journal-title":"Cancer Res"},{"key":"696_CR63","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1146\/annurev.biochem.67.1.545","volume":"67","author":"JL Workman","year":"1998","unstructured":"Workman JL, Kingston RE (1998) Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 67:545\u2013579","journal-title":"Annu Rev Biochem"},{"key":"696_CR64","first-page":"1233","volume":"28","author":"T Sato","year":"2006","unstructured":"Sato T, Suzuki M, Sato Y, Echigo S, Rikiishi H (2006) Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 28:1233\u20131241","journal-title":"Int J Oncol"},{"issue":"3","key":"696_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091325","volume":"9","author":"M Gressette","year":"2014","unstructured":"Gressette M, V\u00e9rillaud B, Jimenez-Pailh\u00e8s AS, Leli\u00e8vre H, Lo KW, Ferrand FR, Gattolliat CH, Jacquet-Bescond A, Kraus-Berthier L, Depil S, Busson P (2014) Treatment of nasopharyngeal carcinoma cells with the histone-deacetylase inhibitor abexinostat: cooperative effects with cis-platin and radiotherapy on patient-derived xenografts. PLoS One 9(3):e91325","journal-title":"PLoS One"},{"key":"696_CR66","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/cbdv.200590118","volume":"2","author":"M Jung","year":"2005","unstructured":"Jung M, Kozikowski A, Dritschilo A (2005) Rational design and development of radiation-sensitizing histone deacetylase inhibitors. Chem Biodivers 2:1452\u20131461","journal-title":"Chem Biodivers"},{"issue":"1","key":"696_CR67","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijrobp.2004.12.088","volume":"62","author":"P Chinnaiyan","year":"2005","unstructured":"Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM (2005) Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 62(1):223\u2013229","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"696_CR68","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/1541-7786.MCR-11-0587","volume":"10","author":"X Chen","year":"2012","unstructured":"Chen X, Wong P, Radany EH, Stark JM, Laulier C, Wong JYC (2012) Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol Cancer Res 10(8):1052\u20131064","journal-title":"Mol Cancer Res"},{"issue":"1","key":"696_CR69","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ijrobp.2010.03.010","volume":"78","author":"C Blattmann","year":"2010","unstructured":"Blattmann C, Oertel S, Ehemann V, Thiemann M, Huber PE, Bischof M, Witt O, Deubzer HE, Kulozik AE, Debus J, Weber KJ (2010) Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 78(1):237\u2013245","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"696_CR70","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1089\/cbr.2009.0629","volume":"24","author":"X Chen","year":"2009","unstructured":"Chen X, Wong P, Radany E, Wong JYC (2009) HDAC inhibitor, valproic acid, induces p53\u2013dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 24(6):689\u2013699","journal-title":"Cancer Biother Radiopharm"},{"key":"696_CR71","doi-asserted-by":"crossref","unstructured":"Losson H, Schnekenburger M, Dicato M, et al (2016) Natural compound histone deacetylase inhibitors (HDACi): synergy with inflammatory signaling pathway modulators and clinical applications in cancer. Molecules 21(11)","DOI":"10.3390\/molecules21111608"},{"issue":"11","key":"696_CR72","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1007\/s10495-013-0866-y","volume":"18","author":"D Wang","year":"2013","unstructured":"Wang D, Zhao M, Chen G, Cheng X, Han X, Lin S, Zhang X, Yu X (2013) The histone deacetylase inhibitor vorinostat prevents TNF\u03b1-induced necroptosis by regulating multiple signaling pathways. Apoptosis 18(11):1348\u20131362","journal-title":"Apoptosis"},{"issue":"12","key":"696_CR73","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1002\/jcp.22684","volume":"226","author":"MD Cantley","year":"2011","unstructured":"Cantley MD, Fairlie DP, Bartold PM, Rainsford KD, le GT, Lucke AJ, Holding CA, Haynes DR (2011) Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. J Cell Physiol 226(12):3233\u20133324","journal-title":"J Cell Physiol"},{"issue":"9","key":"696_CR74","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1002\/jcp.22574","volume":"226","author":"F Bruzzese","year":"2011","unstructured":"Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, di Gennaro E, Budillon A (2011) HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 226(9):2378\u20132390","journal-title":"J Cell Physiol"},{"issue":"4","key":"696_CR75","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1021\/bi400936h","volume":"53","author":"AM Kral","year":"2014","unstructured":"Kral AM, Ozerova N, Close J, Jung J, Chenard M, Fleming J, Haines BB, Harrington P, Maclean J, Miller TA, Secrist P, Wang H, Heidebrecht RW Jr (2014) Divergent kinetics differentiate the mechanism of action of two HDAC inhibitors. Biochemistry 53(4):725\u2013734","journal-title":"Biochemistry"},{"issue":"7","key":"696_CR76","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00405-015-3680-z","volume":"273","author":"RN Rinkel","year":"2016","unstructured":"Rinkel RN, Verdonck-de Leeuw IM, Doornaert P, Buter J, de Bree R, Langendijk JA, Aaronson NK, Leemans CR (2016) Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL-QOL and SHI. Eur Arch Otorhinolaryngol 273(7):1849\u20131855","journal-title":"Eur Arch Otorhinolaryngol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0696-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0696-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0696-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T13:03:39Z","timestamp":1720875819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0696-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,19]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8,15]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0696-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,19]]},"assertion":[{"value":"4 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethical standards"}},{"value":"All authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}